Fibrinogen Caracas V, an abnormal fibrinogen with an Aα 532 Ser→Cys substitution associated with thrombosis

Thrombosis and Haemostasis

Volumn 84, Issue 2, 2000, Pages 263-270

  Marchi, Rita ^a   Lundberg, Ulf ^a   Grimbergen, Jos ^b   Koopman, Jaap ^d   Torres, Argimiro ^c   De Bosch, Norma B ^c   Haverkate, Frits ^a,b   Arocha Piñango, Carmen Luisa ^a  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b TNO   (Netherlands)

^c Banco Metropolitano de Sangre del Distrito Capital   (Venezuela)

^d Pharming Group NV   (Netherlands)

Author keywords

Dysfibrinogenemia; Thrombophilia; Thrombosis

Indexed keywords

BATROXOBIN; FIBRIN; FIBRINOGEN; PLASMINOGEN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOT; CASE REPORT; DYSFIBRINOGENEMIA; ELECTRON MICROSCOPY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; PERMEABILITY; PLASMINOGEN ACTIVATION; POROSITY; PRIORITY JOURNAL; THROMBIN TIME; THROMBOPHILIA; THROMBOSIS; TURBIDITY; VENEZUELA;

EID: 0033852599     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614006     Document Type: Article

References (61)

1. Everse SJ, Spraggon G, Doolittle RF. A three dimensional consideration of variant human fibrinogens. Thromb Haemost 1998; 80: 1-9.
2. Haverkate F, Samama MM. Familial Dysfibrinogenemia and Thrombophilia. Report on a study of the SSC Subcommittee on fibrinogen. Thromb Haemost 1995; 73: 151-61.
3. Koopman J, Haverkate F. Hereditary variants of human fibrinogen. In: Haemostasis and Thrombosis, 3rd ed. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Edinburgh: Churchill Livingstone 1994; 515-29.
4. Soria J, Mirshahi MC, Collet JP, Vasse M, Caen JP, Soria C. In: Dysfibrinogénémies, Manuel d'hemostase. Sampol J, Arnoux D, Boutiere B, eds. Amsterdam: Elsevier, 1995; 489-93.
5. Samama MM, Haverkate F. Hereditary dysfibrinogenemia, Afibrinogenemia, Hypofibrinogenemia and Thrombosis. In: Hypercoagulable states. Fundamental aspects, Acquired disorders and Congenital thrombophilia. Segatchian MJ, Samama MM, Hecker SP, eds. Boca de Raton: CRC Press Inc 1996; 379-83.
6. Liu CY, Wallen P, Handley DA. Fibrinogen New York I: the structural, functional, and genetic defects and a hypothesis of the role of fibrin in the regulation of coagulation and fibrinolysis. In: Fibrinogen-Fibrin Formation and Fibrinolysis. Lane DA, Henschen A, Jasani MK, eds. Berlin: Walter de Gruyter 1986; 79-90.
7. Liu CY, Koehn JA, Morgan FJ. Characterization of fibrinogen New York I. A dysfunctional fibrinogen with a deletion of Bβ (9-72) corresponding to exon II of the gene. J Biol Chem 1985; 260: 4390-6.
8. Koopman J, Haverkate F, Lord ST, Grimbergen J, Mannucci PM. Molecular basis of Fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of Bβ 68 Ala→Thr. J Clin Invest 1992; 90: 238-44.
9. Soria J, Soria C, Hedner U, Nilsson IM, Bergquist D, Samama M. Episodes of increased fibronectin level observed in a patient suffering from recurrent thrombosis related to congenital hypodysfibrinogenemia (fibrinogen Malmö). Brit J Haematol 1985; 61: 727-38.
10. Gandrille S, Priollet P, Capron L, Roncato M, Fiessinger JN, Aiach M. Association of inherited dysfibrinogenemia and Protein C deficiency in two unrelated families. Brit J Haematol 1988; 68: 329-37.
11. J. Paramo Fernandez JA, Cuesta B, Aranda A, Rocha E. Fibrinogen Pamplona II. A new congenital dysfibrinogenemia with abnormal fibrin enhanced plasminogen activation and defective binding of thrombin to fibrin. In: Fibrinogen and its Derivatives. Biochemistry, Physiology and Pathophysiology. Müller-Berghaus G. Scheefers-Borchel U, Seylmar E, Henschen A, eds. Amsterdam, New York, Boston: Excerpta Medica, Elsevier Science Publishers 1986; 25-30.
12. Lijnen HR, Soria J, Soria C, Collen D, Caen JP. Dysfibrinogenemia (Fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromh Haemost 1984; 51: 113-20.
13. Koopman J, Haverkate F, Grimbergen J, Lord ST, Mosesson M, Diorio JP, Siebenlist KS, Legrand C, Soria J, Soria C, Caen JP. Molecular basis for fibrinogen Dusart (Aα 554Arg→Cys) and its association with abnor-mal fibrin polymerization and thrombophilia. J Clin Invest 1993; 91: 1637-43.
14. Engesser L, Koopman J, De Munk G, Haverkate F, Nováková Y, Verheijen JH, Briët E, Brommer EJP. Fibrinogen Nijmegen: congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA. Thromb Haemost 1988; 60: 113-20.
15. Ieko M, Sawada KI, Sakamura S, Yamagishi Y, Isogawa S, Nakagawa S, Satoh M, Yasukuochi T, Matsuda M. Fibrinogen Date: congenital hypodysfibrinogenemia associated with decreased binding of tissue-plasminogen activator. Am J Hematol 1991; 37: 228-33.
16. Soria J, Soria C, Caen JP. A new type of congenital dysfibrinogenemia with defective fibrin lysis-Dusard syndrome: possible relation to thrombosis. Br J Haematol 1983; 53: 575-86.
17. Wada Y, Lord ST. A correlation between thrombotic disease and a specific fibrinogen abnormality (Aα 554 Arg→Cys) in two unrelated kindred Dusart and Chapel Hill III. Blood 1994; 84: 3709-14.
18. Carrell N, Gabriel DA, Blatt PM, Carr ME, Mc Donagh J. Hereditary dysfibrinogenemia in a patient with thrombotic disease. Blood 1983; 62: 439-47.
19. Giddings JC. The investigation of hereditary coagulation disorders. In: Blood Coagulation and Haemostasis. A Practical Guide. Thomson JD, eds. Edinburgh: Churchill Livingstone 1980: 117-57.
20. Ingram GIC. The determination of plasma fibrinogen by the clot weight method. Biochem J 1952; 51: 583-5.
21. Bouvier CA, Gruedlinger J. Etude des phénomènes de coagulation et de fibrinolyse, per une méthode simple d'enregistrement optique. Schweiz Wsch 1963; 93: 1451-5.
22. Gralnick HR, Givelber HM, Shainoff JR, Finlayson JS. Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release. J Clin Invest 1971; 50: 1819-30.
23. Schwartz ML, Pizzo SV, Hill RL, McKee P. The effect of fibrin stabilizing factor on the subunit structure of human fibrin. J Clin Invest 1971; 50: 1506-13.
24. Southan C, Henschen A, Lottspeich F. The search for Molecular defects in Abnormal Fibrinogens In: Fibrinogen, Recent Biochemical and medical Aspects, Henschen A, Graeff H, Lottspeich F. eds. Berlin, Walter de Gruyter 1982; 153-62.
25. Lundberg U, Rodriguez S, Marchi R, Ruíz-Sáez A, Arocha-Piñango CL. Fibrinogen Guarenas I: Partial Characterisation of a New Dysfibrinogenemia with an Altered rate of Fibrinopeptide Release and an Impaired Polymerisation. Thromb Res 78 1995; 95-106.
26. Matsuda M, Baba M, Moritomo K, Nakamikawa C. Fibrinogen Tokyo II. An Abnormal Fibrinogen with an Impaired Polymerisation site on the aligned DD domain of fibrin molecules. J Clin Invest 1983; 72: 1034-41.
27. Kazal LA, Amsel S, Miller OP, Tocantins LM. Preparation and some properties of fibrinogen precipitated from human plasma by glycine. Proc Soc Exp Biol Med 1963; 113: 989-94.
28. Schägger H, Von Jagow G. Tricine-sodium dodecyl sulphate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kD. Anal Biochem 1987; 166: 368-79.
29. Deutsch GD, Mertz ET. Plasminogen: Purification from Human Plasma by Affinity Chromatography. Science 1970; 170: 1095-6.
30. Suenson E, Thorsen S. The Course and Prerequisites of Lys-plasminogen Formation during Fibrinolysis. Biochemistry 1988; 27: 2435-43.
31. Angles-Cano E. A Spectrophotometric Solid-Phase Fibrin-Tissue Plasminogen Activator Activity Assay (SOFIA-tPA) for High-Fibrin-Affinity Tissue Plasminogen Activators. Anal Biochem 1986; 153: 201-10.
32. Pirie-Shepherd SR, Jett AA, Andon NL, Pizzo SV. Sialic acid Content of Plasminogen 2 Glycoforms as a regulator of fibrinolytic Activity. J Biol Chem 1995; 270: 5877-81.
33. Branson HE. The structural components of the "Dirty" fiber of fibrinogen Seattle. A new model of fibrin assembly. Thromb Haemost 1979; 42: 1378-87.
34. Blombäck B, Okada M. Fibrin gel structure and clotting time. Thromb Res 1982; 25: 51-70.
35. Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Aslund N. Native fibrin gel networks observed by 3D microscopy, permeability and turbidity. Biochem Biophys Acta 1989; 997: 96-110.
36. Blombäck B, Blombäck M: Purification of human and bovine fibrinogen. Arkiv för Kemi 10; 1956: 415-43.
37. Carr ME, Hermans J. Size and density of fibrin fibers from turbidity. Macromolecules 1978; 11: 46-50.
38. Nair CH, Azhar A, Dhall DP. Studies of Fibrin Network Structure in Human Plasma. Part One: methods for Clinical Application. Thromb Res 1991; 64: 455-76.
39. Gustavson S, Proper JA, Bowie EJW, Sommers SS. Parameters Affecting the Yield of DNA from Human Blood. Anal Biochem 1987; 165: 294-9.
40. Kirshbaum NE, Foster PA. The polymerase chain reaction with sequence-specific primers for the detection of the Factor V mutation associated with activated Protein C Resistance. Thromb Haemost 1995; 74: 874-8.
41. Bellisimo B, Kirshbaum N, Foster P: Improved method for Factor V Leiden Typing by PCR-SSP. Thromb Haemost 1996; 75: 520-1.
42. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A Common Genetic Variation in the 3'-Untranslated Region of the Prothrombin Gene is Associated With Elevated Plasma Prothrombin Levels and an Increase in Venous Thrombosis. Blood 1996; 88: 3698-703.
43. Veklich YI, Gorkun OV, Medved LV, Nieuwenhuizen W, Weisel JW. Carboxy-terminal portions of the α chains of fibrinogen and fibrin. Localisation by electron microscopy and the effects of isolated αC fragments on polymerisation. J Biol Chem 1993; 268: 13577-85.
44. Gorkun OV, Veklich YI, Medved LV, Henschen AH, Weisel JW. Role of the αC domains of fibrin in clot formation. Biochemistry 1994; 33: 6986-97.
45. Blombäck B, Banerjee D, Carlsson K, Hamsten A, Hessel B, Procyk R, Silveira A, Zacharski L. Native fibrin gel networks and factors influencing their formation in health and disease. In: Liu CY, Chien S (eds): Fibrinogen, Thrombosis, Coagulation, and Fibrinolysis, New York, Plenun Press, 1990, p 1.
46. Woodhead JL, Nagaswami C, Matsuda M, Arocha-Piñango CL, Weisel W. The ultrastructure of fibrinogen Caracas II molecules, fibres, and clots. J Biol Chem 1996; 271: 4946-53.
47. Collet JP, Soria J, Mirshahi M, Hirsch M, Dagonnet FB, Caen J, Soria C. Dusart Syndrome: a new concept of the relationship between fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 1993; 82: 2462-69.
48. Collet JP, Woodhead JL, Soria J, Soria C, Mirshahi M, Caen JP, Weisel JW. Fibrinogen Dusart: Electron microscopy of molecules, fibres and clots, and viscoelastic properties of clots. Biophys J 1996; 70: 500-10.
49. Furlan M, Steinmann C, Jungo M, Bogli C, Baudo F, Redaelli R, Fedeli F, Lämmle B. A frameshift mutation in Exon V of the A alpha-chain gene leading to truncated Aα-chains in the homozygous dysfibrinogen Milano III. J Biol Chem 1994; 269: 33129-34.
50. Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord ST. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids Aα 461-610 (Lys 461 AAA→stop TAA). Blood 1992; 80: 1972-9.
51. Furlan M, Steinmann C, Jungo M, Lämmle B. Binding of calcium ions and their effect on clotting of fibrinogen Milano III, a variant with truncated Aα-chains. Blood Coag Fibrinol 1996; 7: 331-5.
52. n-heteromultimers and the alpha-chain-linked albumin.gamma complex, and disturbed protofibril assembly resulting in acquisition of plasmin resistance relevant to thrombophila. Blood 1998; 91: 3282-8.
53. Maekawa H, Yamazumi K, Muramatsu S, Kaneko M, Hirata H, Takahashi N, Bosch N, Carvajal Z, Ojeda A, Arocha-Piñango CL, Matsuda M. An Aα Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen, Fibrinogen Caracas II, characterised by impaired fibrin gel formation. J Biol Chem 1991; 266: 11575-81.
54. Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267: 24259-63.
55. Pring JB, Gaffney PJ. Fibrin formation-Influence of various components of coagulation and fibrinolysis on clot structure. Thromb Haemost 1991; 65: 737-45.
56. Gabriel DA, Muga K, Boothroyd EM. The influence of fibrin mass/length ratio on fibrinolysis. Thromb Haemost 1992; 267: 24259-63.
57. Blombäck B. Fibrinogen and fibrin-proteins with complex roles in hemostasis and thrombosis. Thromb Res 1996; 83: 1-75.
58. Hessel B, Silveira AMV, Carlsson K, Oksa H, Rasi V, Vahtera E, Procyk R, Blombäck B. Fibrinogen Tampere- A dysfibrinogenemia with defective gelation and thromboembolic disease. Thromb Res 1995; 78: 323-39
59. Benson MD, Liepnieks J: Uemichi T, Wheeler G, Correa R. Hereditay Renal amyloidosis Associated with a Mutant Fibrinogen α-chain. Nat Genet 1993; 3: 252-5
60. Uemichi T, Liepnieks JJ, Benson MD. Hereditary Renal Amyloidosis with a Novel variant fibrinogen. J Clin Invest 1994; 93: 731-6
61. Hamidi AL, Liepnieks JJ, Uemiehi T, Rebibou JM, Justraho E, Droz D, Mousson C, Chalopin JM, Benson MD, Delpech M, Grateau G. Renal Amyloidosis with a Frame Shift Mutation in Fibrinogen Aα-chain gene producing a Novel Amyloid Protein. Blood 1997; 90: 4799-805.